Fig. 4: B cell depletion enhances STING agonism with dual PD-1/VEGFR2 blockade in the RIL-175 murine HCC model.

a Experimental design of B cell depletion and STING agonism with dual PD-1/VEGFR2 blockade. b Representative high-frequency ultrasound images of the RIL-175 orthotopic tumor-bearing C57Bl/6 mice at day 30. Tumor regions were delineated by dotted lines. n = 9/group. c Tumor growth kinetics after treatment: the combination of STING agonist, dual anti-PD-1/anti-VEGFR2, and B cell depletion group achieved a complete tumor response in all mice, demonstrating a significantly superior tumor growth delay than other groups. n = 9/group. d Overall survival of RIL-175 murine HCC-bearing mice after treatment: STING agonist with dual anti-PD-1/anti-VEGFR2 plus B cell depletion induced a significant survival benefit than those without B cell depletion or control groups. P-value from log-rank test, n = 9/group. e A schematic for tumor rechallenge to the mice that have survived long-term from the initial survival cohort. f Comparison of tumor volumes detected by ultrasound 9 days after tumor rechallenge in long-term survivors (n = 9) and age-matched control mice (n = 7). P-value from two-sided Mann–Whitney U test. Data from the box plot are presented as mean ± SD. Source data are provided as a Source Data file.